Stocks To Buy Now

Blog


Net Element, Inc. (NETE) Launches Aptito v. 2.9, Integrates Apple Pay™ and Other Key Upgrades

Net Element (NASDAQ: NETE), operator of a payments-as-a-service transactional and value-added services platform for small to medium enterprise in the US, Russian Federation and other international markets, has launched a new version of its cloud-based Aptito point-of-sale system for the restaurant industry.

Aptito v. 2.9 provides universal payment acceptance and numerous restaurant productivity upgrades at a flexible pricing structure that allows easier access for merchants with diverse needs and resources.

Aptito is a mobile iPad and iPhone restaurant productivity and omni-channel payment processing solution that improves restaurant efficiency, lowers costs and enhances customer experience.

The newest version rounds out the technology’s payment acceptance options with the integration of EMV chip technology and Apple, Inc.’s (NASDAQ: AAPL) Apple Pay™ into its transactional processing platform.

Direct Aptito integration with payments processor Total System Services (TSYS) allows merchants to bypass third-party gateway fees.

Aptito v. 2.9 product features also include:

• WiFi enabled interactive kitchen display
• Multiple happy hour pricing management
• Bluetooth printer integration
• Improved employee management including automated time card and shift reports

“These upgrades provide a competitive edge to the product and should facilitate Aptito sales efforts and increase transactional revenue,” Oleg Firer, Net Element CEO, stated in the news release. “By delivering these tools our goal is to help grow the business of our customers and assure greater transactional volume for Net Element.”

For more information visit www.netelement.com

From Our Blog

Nutriband Inc. (NASDAQ: NTRB) Innovating Abuse-Deterrent Drug Delivery in a Shifting Opioid Landscape

May 9, 2025

A Market Demanding Safer Opioid Solutions The opioid crisis remains a critical public health challenge in the U.S. and globally, prompting a series of new regulatory measures designed to improve safety and reduce misuse. In early 2025, the FDA approved Journavx (suzetrigine), a first-in-class non-opioid painkiller offering patients safer alternatives to opioids. Additionally, opioid manufacturers […]

Rotate your device 90° to view site.